GlassScriptPhysician profile
Elesa Lynee Ignowski
NPI 1942685151
$3,090.84
in general payments reported to CMS, 2019-2025
22 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $168 · 2023: $622 · 2024: $1,133 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799 · Education: $21.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,799.04 |
| Education | $21.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.09 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $565.40 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $362.59 | 2023-2025 | Caplyta |
| Corium, LLC | $263.30 | 2023-2025 | Azstarys |
| Lundbeck LLC | $253.21 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $175.56 | 2024-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $163.64 | 2022-2025 | Ingrezza |
| Janssen Scientific Affairs, LLC | $117.17 | 2025 | Spravato |
| Vanda Pharmaceuticals INC. | $113.40 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $109.86 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $76.19 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $37.18 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $36.52 | 2024 | |
| Pfizer INC. | $30.95 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.66 | 2025 | Austedo Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $18.47 | 2025 | Loreev Xr |
| Nestle Healthcare Nutrition INC. | $16.93 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.71 | 2024 | Quviviq |
| Novo Nordisk INC | $15.61 | 2021 | |
| Lilly USA, LLC | $14.67 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.31 | 2025 | Relexxii |
| Biohaven Pharmaceuticals, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elesa Ignowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.